ALK(SZ:002940) Ge Long Hui·2025-08-03 08:11Core Viewpoint - The stock of Anglikang (002940.SZ) experienced significant price fluctuations, with a cumulative increase of over 20% in two consecutive trading days, prompting an investigation by the company's board of directors [1] Group 1: Stock Trading Anomalies - The stock price deviation occurred on July 31 and August 1, 2025, indicating abnormal trading activity [1] - The company confirmed that there were no undisclosed significant matters that could have influenced the stock price [1] - The operational status of the company remains normal, with no significant changes in its main business or external operating environment [1] Group 2: Innovation Drug Projects - The company is currently focused on its innovative drug project ALK-N001, which received clinical trial approval in April 2025 and is in Phase I trials [2] - There is investor interest in the ALK-N002 project, which is part of the company's adjusted fundraising investment plan for 2025, with multiple candidate drugs under consideration [2] - The company emphasizes the long cycle, high investment, and uncertainty associated with innovative drug development, urging investors to be aware of investment risks [2]